

FORM 51 – 102F3

MATERIAL CHANGE REPORT

1. Name and Address of Company

bioMmune Technologies Inc.
1780 – 400 Burrard Street
Vancouver, BC V6C 3A6

2. Date of Material Change

October 11, 2015

3. News Release

A news release dated October 11, 2015 was disseminated through Marketwired and was filed via SEDAR on October 13, 2015.

4. Summary of the Material Change

BioMmune Technologies Inc. Announces Non-Brokered Private Placement.

5. Full Description of the Material Change

BioMmune Technologies Inc. (the "Company") (TSX VENTURE:IMU), announces a non-brokered private placement of up to 2,000,000 units (each a "Unit") at a price of \$0.30 per Unit for gross proceeds of up to \$600,000. Each Unit will consist of one common share and one common share purchase warrant (each a "Warrant"). Each Warrant entitles the holder to purchase one additional common share of the Company at a price of \$0.40 per share for a period of 24 months from the date of closing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company's shares are trading at or above a volume weighted average price of \$0.60 for 10 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release.

Certain directors and officers of the Company intend to acquire the Units under the Private Placement. Any such participation would be considered to be a "related party transaction" as defined under Multilateral Instrument 61 -101 *Protection of Minority Security Holders in Special Transactions* ("MI 61-101"). The transaction will be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of any shares issued to, or the consideration paid by such persons, will exceed 25% of the Company's market capitalization.

The proceeds from the sale of units will be added to working capital in furtherance of the Company's business. The securities to be issued under the placement will be subject to a four-month hold period and the private placement is subject to the acceptance of the TSX Venture Exchange.

6. Reliance on subsection 7.1(2) or (3) of National Instrument 51 – 102

N/A

7. Omitted Information

N/A

8. Executive Officer

Dr. Reinhard Gabathuler, President
Phone: (514) 963-6177

9. Date of Report

October 21, 2015